Carnick & Kubik’s Antares Pharma, Inc. ATRS Stock Holding History

Carnick & Kubik’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-14,000	Closed	-$23.8K	–	352
2015 Q3	$23.8K	Buy	+14,000	New	+$27.4K	0.02%	257

Other funds holding ATRS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carnick & Kubik's ATRS Position: Q4 2015 in Review

Carnick & Kubik sold out of Antares Pharma, Inc. (ATRS) in Q4 2015, closing a stake of 14,000 shares — an estimated $23.8K sold.

Carnick & Kubik first reported a position in ATRS in Q3 2015 and held it in 1 quarter. The position peaked at $23.8K in Q3 2015. 88 funds tracked by Wall St. Rank hold ATRS as of Q4 2015.

Carnick & Kubik reported no remaining Antares Pharma, Inc. position as of Q4 2015 after selling out during the quarter.
Carnick & Kubik sold 14,000 Antares Pharma, Inc. shares in Q4 2015, an estimated $23.8K.
Carnick & Kubik first reported a position in Antares Pharma, Inc. in Q3 2015 and held it in 1 quarter.
Carnick & Kubik's Antares Pharma, Inc. position peaked at $23.8K in Q3 2015.
88 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2015.

Based on Carnick & Kubik's 13F filing for Q4 2015, filed 11 Feb 2016.